FRIDAY, June 12, 2026 (NewsDay News) — Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is effective in adults with type 2 diabetes inadequately controlled with diet and exercise, taking metformin with sodium and colucoLT2 inhibitors (2 g) or without metformin. According to three studies published online June 7, using basal insulin Lancet Diabetes and Endocrinology and Lancet which coincides with the annual meeting of the American Diabetes Association, which was held from June 5 to 8 in New Orleans.
Vanita R. Aroda, MD, of Brigham and Women’s Hospital in Boston, and colleagues randomized adults with type 2 diabetes inadequately controlled by diet and exercise to receive once weekly subcutaneous caglilintide 2.4 mg plus semaglutide 2.4 mg, caglilintide plus semaglutide 2.4 mg, semaglutide plus semaglutide placebo for 40 weeks (62, 63 and 64 participants). The researchers found that the mean estimated change in hemoglobin A1c (HbA1c) after week 40 was -1.8, -1.5, and -0.1 percentage points for cagrilintide-semaglutide 2.4 mg each, 1.0 mg, and placebo, respectively.
John B. Busse, MD, of the University of North Carolina School of Medicine at Chapel Hill and colleagues randomly assigned 2,713 adults with type 2 diabetes who were taking metformin with or without SGLT2i and who were overweight or obese to receive cagrilintide-semaglutide, semaglutide, semaglutide, semaglutide. 68 weeks. The researchers found that the mean change in HbA1c was significantly greater with cagrilintide-semaglutide (2.4 mg each) than with semaglutide 2.4 mg (−1.91 versus −1.75 percentage points). In a third study, Julio Rosenstock, MD, of the University of Texas Southwestern Medical Center in Dallas and colleagues found that the mean reduction in HbA1c with cagrilintide-semaglutide (each 2.4 mg and each: 1.0 mg: −2.33 and −2.10 percent per week, respectively) was significantly greater (640%). 274 adults with type 2 diabetes using basal insulin.
“These findings support a potential new therapeutic tool to improve HbA1c levels below 7 percent in such a challenging population,” Rosenstock said in a statement.
Several authors of all three studies disclosed relationships with biopharmaceutical companies, including Novo Nordisk, which developed cagrilintide and funded the study.
Abstract / Full Text – Aroda (subscription or payment may be required)
Abstract / Full Text – Buso (subscription or payment may be required)
Abstract / Full Text – Rosenstock (subscription or payment may be required)
